Candel Therapeutics (CADL) vs Geron (GERN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Candel Therapeutics (CADL) has outperformed Geron (GERN) over the past year, gaining 51.8% versus a loss of 11.9%. Over five years, CADL leads with a +1.1% price change compared with -13.1% for GERN. Geron is the larger company by market cap ($787.0 million vs $760.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CADL | GERN |
|---|---|---|
| Share price | $9.94 | $1.23 |
| Market cap | $760.59M | $787.03M |
| 1-day change | +2.90% | +0.41% |
| YTD return | +75.93% | -7.20% |
| 1-year return | +51.76% | -11.87% |
| 5-year return | +1.12% | -13.12% |
| Forward P/E | — | 30.63 |
| EPS (TTM) | $-1.50 | $-0.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.00 | $2.01 |
| 52-week low | $4.35 | $1.04 |
| Distance from 52-week high | -29.00% | -39.05% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +118.81% | +246.94% |
| Average volume | 1.21M | 10.06M |
| Shares outstanding | 76.52M | 642.47M |
| Employees | 55 | 258 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CADL has outperformed GERN by 63.6 percentage points over the past year.
About Candel Therapeutics
CADL stock →Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 55 employees
About Geron
GERN stock →Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
CADL vs GERN FAQ
Which is bigger, Candel Therapeutics or Geron?
Geron (GERN) is larger, with a market capitalization of $787.03M compared with $760.59M for Candel Therapeutics (CADL).
Which stock has performed better over the past year, CADL or GERN?
CADL returned +51.76% over the past 12 months, compared with -11.87% for GERN (price return, excluding dividends). Past performance does not predict future results.
Are Candel Therapeutics and Geron in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Candel Therapeutics and Biotechnology: Pharmaceutical Preparations for Geron.